Stay updated with breaking news from Marc Gitzinger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Superbug infections kill more people now than HIV/AIDS or malaria. We need new antibiotics and other drugs, but developers lack incentives. A new policy could fix that.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
/PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicrobials,...
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investmentBASEL, Switzerland, January 05, 2023 / B3C newswire / -- BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research a...
BioVersys will use the Unyvero HPN in its drug trial to test hospitalized trial candidates for antibiotic-resistant Acinetobacter infections.